Background: Rett disorder (RD) is a progressive neurodevelopmental entity caused by mutations in the MECP2 gene. It has been postulated that there are alterations in the levels of certain neurotransmitters and folate in the pathogenesis of this disease. Here we re-evaluated this hypothesis. Patients and methods: We evaluated CSF folate, biogenic amines and pterines in 25 RD patients. Treatment with oral folinic acid was started in those cases with low folate. Patients were clinically evaluated and videotaped up to 6 months after therapy. Results: CSF folate was below the reference values in 32% of the patients. Six months after treatment no clinical improvement was observed. Three of the four patients with the R294X mutation had increased levels of a dopamine metabolite associated to a particular phenotype. Three patients had low levels of a serotonin metabolite. Two of them were treated with fluoxetine and one showed clinical improvement. No association was observed between CSF folate and these metabolites, after adjusting for the patients age and neopterin levels. Conclusion: Our results support that folinic acid supplementation has no significant effects on the course of the disease. We report discrete and novel neurotransmitter abnormalities that may contribute to the pathogenesis of RD highlighting the need for further studies on CSF neurotransmitters in clinically and genetically well characterized patients.
Introduction
Rett syndrome is a progressive neurodevelopmental disorder clinically defined by criteria revised in 2002
[1]. In 1999 its aetiology was first established: mutations of the methyl-CpG binding protein 2 (MeCP2) gene (MECP2), which maps to Xq28 [2] . Since then, patients meeting the revised diagnostic criteria can be divided in two groups: those with a detected MECP2 mutationRett disorder patients (RD) and those without it -Rett syndrome patients (RTT).
Nomura et al. [3] were among the first to suggest that neurotransmitter anomalies could form the chemical 
